Here, CD40 activation of autologous B-CLL tumor cells may upregulate tumor-associated antigens, such as survivin or RHAMM (receptor for hyaluronic acid-mediated motility) [24,25] which may be expressed in vivo by B-CLL SP cells, resulting in their depletion following immunization. The gene discussed is CD40; the disease is B-cell chronic lymphocytic leukemia.